Original Investigation

Rilvegostomig Plus Trastuzumab-Deruxtecan for Early-Stage Breast Cancer

JAMA Oncology 10.1001/jamaoncol.2026.4258

October 22, 2026 at 11:00 AM EDT

Read the full article

Does first treatment with rilvegostomig (an immune-directed, bispecific antibody) plus trastuzumab-deruxtecan (an antibody drug conjugate) (RT-DXd) improve response in high-risk early breast cancer (EBC) with ERBB2-low/ultralow expression? In this randomized clinical trial of 182 individuals with EBC, pathologic complete response rates were high (79%) in immune-positive EBC, regardless of treatment sequence. Among immune-sensitive responders to RT-DXd, 21 (62%) avoided standard chemotherapy. The trial results suggest that RT-DXd is highly active in immune-positive disease regardless of hormone receptor or ERBB2-low/ultralow status, with mostly low-grade toxic effects, and it could be a shorter, less toxic neoadjuvant therapy option; whereas immune-negative tumors responded poorly, highlighting the need for new therapies.

Corresponding Author: Laura J. Esserman, MD, MBA, Precision Cancer Medicine Building, 1825 Fourth St, 3rd Floor, San Francisco, CA 94158 (laura.esserman@ucsf.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2026.4258

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks